Tianjin Zhongjin Biology Development

Tianjin Zhongjin Biology Development Co., Ltd. (TZBD) is a medical device and biotechnology company based in the Tianjin Economic and Technological Development Zone, China. Founded in 2003, the company specializes in the production and distribution of Reconstituted Bone Xenograft (RBX), a medical device used to accelerate bone healing and treat bone defects. In 2004, TZBD was acquired by Genex Pharmaceutical, Inc. (OTC: GENX), becoming its primary operating subsidiary. The company also manufactures a range of dental consumables, including gutta percha points and absorbent paper points for endodontic procedures. TZBD's products are widely utilized in the Chinese healthcare market, with a distribution network covering over 500 hospitals across 30 provinces. The company continues to focus on expanding its portfolio of bone grafting and dental treatment solutions.